Affinity Asset Advisors LLC Buys 150,000 Shares of Celldex Therapeutics, Inc. $CLDX

Affinity Asset Advisors LLC increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 42.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 500,000 shares of the biopharmaceutical company’s stock after purchasing an additional 150,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Celldex Therapeutics were worth $15,860,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in CLDX. Tudor Investment Corp ET AL purchased a new stake in shares of Celldex Therapeutics during the 3rd quarter valued at approximately $818,000. SG Americas Securities LLC grew its stake in Celldex Therapeutics by 143.2% in the 4th quarter. SG Americas Securities LLC now owns 47,340 shares of the biopharmaceutical company’s stock valued at $1,286,000 after buying an additional 27,872 shares in the last quarter. PSP Research LLC bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at $553,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Celldex Therapeutics during the 1st quarter valued at $1,433,000. Finally, Candriam S.C.A. purchased a new stake in Celldex Therapeutics during the 1st quarter worth about $8,846,000.

Celldex Therapeutics Stock Down 0.4%

NASDAQ:CLDX opened at $35.28 on Friday. The company has a fifty day moving average of $33.64 and a 200 day moving average of $30.68. Celldex Therapeutics, Inc. has a 52 week low of $19.72 and a 52 week high of $40.30. The firm has a market capitalization of $2.77 billion, a P/E ratio of -8.28 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, analysts anticipate that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Canaccord Genuity Group decreased their target price on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday. UBS Group raised their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday, July 17th. Finally, Guggenheim raised their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $52.77.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.